---
title: "Black Diamond Therapeutics, Inc. (BDTX.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/BDTX.US.md"
symbol: "BDTX.US"
name: "Black Diamond Therapeutics, Inc."
industry: "生物技術"
---

# Black Diamond Therapeutics, Inc. (BDTX.US)

| Item | Detail |
|------|--------|
| Industry | 生物技術 |
| Location | 美股市場 |
| Website | [www.blackdiamondtherapeutics.com](https://www.blackdiamondtherapeutics.com) |

## Company Profile

黑鑽石治療公司（Black Diamond Therapeutics, Inc.）是一家臨床階段的腫瘤學公司，專注于為具有基因定義腫瘤的患者發現和開發 MasterKey 療法。該公司的主要產品候選藥物是 BDTX-1535，這是一種能夠穿透大腦的表皮生長因子受體 MasterKey 抑制劑，目前正在進行針對表皮生長因子受體突變的非小細胞肺癌的二期臨床試驗，同時也在進行治療膠質母細胞瘤的一期臨床試驗。公司還在開發 BDTX-4933，這是一種針對固體腫瘤中 KRAS、NRAS 和 BRAF 改變的能夠穿透大腦的 RAF MasterKey 抑制劑，目前處于一期臨床試驗階段。此外，公司還在開發 ...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:13.000Z

**Overall: B (0.38)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 45 / 403 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% |  |
| Net Profit YoY | 129.41% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 1.04 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 131.04M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 70.00M |  |


**Multi Score**: B

#### Profit Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 19.23% | A |
| Profit Margin | 30.71% | A |
| Gross Margin | 0.00% | E |

#### Growth Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% | C |
| Net Profit YoY | 129.41% | A |
| Total Assets YoY | 14.39% | B |
| Net Assets YoY | 29.48% | A |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 325.61% | C |
| OCF YoY | 0.00% | C |

#### Operating Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.47 | C |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 20.02% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Black Diamond Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "19.23%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "30.71%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "C",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "129.41%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "14.39%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "29.48%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "325.61%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "0.00%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "C",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.47",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "20.02%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | ADMA生物制藥 (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | Rigel制藥 (US.RIGL) | A | A | A | C | B | A |
| 05 | OpGen (US.OPGN) | B | A | A | A | B | A |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 6.10 | 9/604 | 26.25 | 12.58 | 7.08 |
| PB | 1.04 | 83/604 | 1.40 | 1.16 | 1.00 |
| PS (TTM) | 1.87 | 49/604 | 3.06 | 2.21 | 1.97 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-20T05:00:00.000Z

Total Analysts: **9**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 6 | 67% |
| Overweight | 2 | 22% |
| Hold | 1 | 11% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.31 |
| Highest Target | 13.00 |
| Lowest Target | 6.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/BDTX.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/BDTX.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/BDTX.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
